An observational study in Pulmonary Hypertension and Pulmonary Arterial Hypertension, sponsored by Chinese Pulmonary Vascular Disease Research Group. Recruiting at 1 site in China. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-22.
Sponsored by Chinese Pulmonary Vascular Disease Research Group · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 76 studies in Pulmonary Arterial Hypertension with a site in China — 19 open to participants now, 24 under way, 3 of them phase 3. Pulmonary Arterial Hypertension · China.
Among the 76 studies in Pulmonary Arterial Hypertension with a site in China, this one is the 5th largest by planned enrollment of the 20 observational ones that give a count, is one of 8 that started in 2022, is one of 20 observational ones, reaches primary completion later than 17 of the 23 other live ones, and was the 56th registered.
701 studies on the registry are indexed under Pulmonary Arterial Hypertension; 141 are open to participants now.
Browse Pulmonary Arterial Hypertension studies →19 of the 76 studies in Pulmonary Arterial Hypertension with a site in China are open now. Recruiting first, the newest first:
Chinese Pulmonary Vascular Disease Research Group · Sites in China
Ages 18+
China National Center for Cardiovascular Diseases · Sites in China
Ages 18+
ImmuneCare Biopharmaceuticals (Shanghai) Co., Ltd. · Sites in China
Ages 18–75
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18–80
Pulnovo Medical (Wuxi) Co., Ltd. · Sites in China
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
76 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 11 · Phase 3 27 · Phase 4 6
First in 2004; this study’s year is marked. 8 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 2,000 is above the median of 104 across 181 observational studies indexed under Pulmonary Arterial Hypertension.
Median enrollment 148 across the 56 interventional studies, 495 across the 20 observational. Of the 37 that completed or were terminated, 20 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
41 of 76 have an industry lead sponsor. The 10 most frequent:
Chinese Pulmonary Vascular Disease Research Group is the lead sponsor of 17 studies on the registry; 11 are open to participants now.
Chinese Pulmonary Vascular Disease Research Group has 5 studies filed under Pulmonary Arterial Hypertension — fewer than ten, so there is no comparison to draw.
7 of the studies in Pulmonary Arterial Hypertension with a site in China that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03683186Phase 3United TherapeuticsA Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension | 2026-12 |
| NCT05179876Phase 3ActelionA Study Providing Treatment Access in Participants With Pulmonary Hypertension Completing a Parent Study and Having no Other Option | 2027-01-31 |
| NCT06554301China National Center for Cardiovascular DiseasesA Study on the Efficacy and Safety of Empagliflozin in the Treatment of Pulmonary Arterial Hypertension | 2026-12 |
| NCT06528418ChromX HealthIdentification of Multiple Pulmonary Diseases Using Volatile Organic Compounds Biomarkers in Human Exhaled Breath | 2026-12-30 |
| NCT07184814China-Japan Friendship HospitalClinical Features and Prognosis of Takayasu's Arteritis With Pulmonary Arteries Involvement | 2026-12-31 |
Add all 7 to your calendar (.ics) → With an account.
Among the 76 studies in Pulmonary Arterial Hypertension with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Pulmonary hypertension represents a challenging and heterogeneous condition that is associated with high mortality and morbidity if left untreated. Artificial intelligence is used to study and develop theories and methods that simulate and extend human intelligence, which is being applied in fields related to cardiovascular diseases. The study intends to combine multimodal clinical data of patients who undergo right heart catheterization at Fuwai Hospital with artificial intelligence techniques to create programs that can screen and diagnose pulmonary hypertension.
Patients with pulmonary hypertension (PH) represent a challenging and heterogeneous cohort with high morbidity and mortality if left untreated. To make a definitive diagnosis of PH, one needs to conduct an invasive right heart catheterization (RHC) in order to assess the mean pulmonary artery pressure (mPAP). As PH occurs sporadically in various medical conditions, including connective tissue disease, and congenital heart disease, and presenting symptoms are non-specific, there is a need to raise the suspicion of PH early in the community. For this reason, noninvasive tools that are widely available for upfront screening would be ideal to enable timely diagnosis of PH. Transthoracic echocardiography has emerged as the mainstay for screening of PH, yet the sensitivity and specificity of this approach remain limited even in experienced hands. As high-throughput technologies advance and access to PH big data improve, it will be critical to prudently select artificial intelligence approaches for data analysis, visualization, and interpretation. By combining the multimodal clinical data (such as indicators from chest X-ray, electrocardiography, and echocardiography), this study aims to develop artificial intelligence-assisted programs to assist the screening and diagnosis of PH, and to evaluate its diagnostic accuracy for PH as compared with RHC, and to estimate whether this approach outperforms the conventional echocardiographic method.
701 studies on the registry are indexed under Pulmonary Arterial Hypertension; 141 are open to participants now.
This study's planned enrollment of 2,000 is above the median of 104 across 181 observational studies indexed under Pulmonary Arterial Hypertension.
Browse Pulmonary Arterial Hypertension studies →Chinese Pulmonary Vascular Disease Research Group is the lead sponsor of 17 studies on the registry; 11 are open to participants now.
Compared within Pulmonary Arterial Hypertension, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Hypertension, Pulmonary. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Adult patients previously received chest X-rays, electrocardiography, echocardiography, other routine examinations, and RHC at the Fuwai Hospital, CAMS \& PUMC, Beijing, China.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
A series of routine examinations, including chest X-ray, electrocardiography, echocardiography, etc, would be performed on consecutive patients at Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. An RHC with an mPAP of \>20 mmHg would confirm the diagnosis of PH. All these data will be collected as a source for machine learning or other artificial intelligence-assisted programs.
Diagnostic Test: Right heart catheterization
A series of routine examinations, including chest X-ray, electrocardiography, echocardiography, etc, would be performed on consecutive patients at Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. An RHC with an mPAP of ≤20 mmHg would confirm the absence of PH. All these data will be collected as a source for machine learning or other artificial intelligence-assisted programs.
Diagnostic Test: Right heart catheterization
RHC is commonly used essential test to make gold-standard diagnosis of PH with mPAP \>20 mmHg. All multimodal data from patients eligible for inclusion would be randomly assigned to development datasets (70% of the study population) to train the artificial intelligence models for the detection of PH, which would be validated and tested by other datasets (30% of the study population).
Accuracy of diagnosis by artificial intelligence-assisted algorithm
The investigators will calculate the area under the receiver operating characteristic curve of diagnosis by artificial intelligence-assisted algorithm and compare this index between artificial intelligence-assisted algorithm and RHC.
Time frame: Baseline
Sensitivity of diagnosis by artificial intelligence algorithm
The investigators will calculate the sensitivity of diagnosis by artificial intelligence-assisted algorithm and compare this index between artificial intelligence-assisted algorithm and RHC.
Time frame: Baseline
Specificity of diagnosis by artificial intelligence algorithm
The investigators will calculate the sensitivity of diagnosis by artificial intelligence-assisted algorithm and compare this index between artificial intelligence-assisted algorithm and RHC.
Time frame: Baseline
Plan to share: Undecided
Started Jun 2022 (actual). Primary completion is estimated for Dec 2028, 78 months after the start.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 22, 2026: primary completion Dec 2025 → Dec 2028 and completion Dec 2025 → Dec 2028.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pulmonary Arterial Hypertension →
Chinese Pulmonary Vascular Disease Research Group